The BioInnovation Institute (BII) is a Novo Nordisk Foundation-funded incubator that provides up to €2.5M in non-dilutive funding and hands-on support to early-stage biotech startups, aiming to accelerate the translation of innovative life science research into commercial ventures. It exists to bridge the gap between academic discovery and company building, particularly in deep tech areas like AI-driven drug discovery, by offering capital, lab space, and access to a strong biopharma network.

- Scientific excellence and novelty: The technology must be groundbreaking and address a significant unmet need in life sciences. - Commercial potential: Clear path to market, with a scalable business model and realistic revenue projections. - Team strength: Preferably a multi-founder team with complementary expertise (scientific, business, and technical); sole founders are at a disadvantage unless they have a strong advisory board or clear plan to recruit co-founders. - Stage readiness: Typically requires at least a proof-of-concept validated; pre-incorporation is acceptable but must have a clear incorporation timeline and legal structure plan. - Alignment with BII's focus areas: Biotech, health tech, and deep tech; AI/ML applied to drug discovery is a strong fit. - Network and partnerships: Existing collaborations with pharma, research institutes, or hospitals are a plus (e.g., Servier, Paris-Saclay). - Impact and scalability: Potential to address global health challenges (e.g., antimicrobial resistance, oncology) and generate significant societal or economic impact.

- BII typically funds early-stage biotech startups with a strong scientific foundation, often spun out from universities or research institutes in the Nordics and EU. Past winners include companies developing novel therapeutics, diagnostics, and platform technologies (e.g., AI-driven drug design, gene editing, microbiome therapies). Named examples from BII's portfolio include: 'Adcendo' (antibody-drug conjugates), 'Cysbio' (cell engineering), and 'SpliceBio' (RNA splicing). These startups usually have co-founders with PhDs or MDs, and many have secured follow-on funding from VCs.

The ideal BII applicant is a multi-founder team with a strong scientific co-founder (e.g., PhD in computational biology or structural biology) and a business-oriented co-founder, with a validated proof-of-concept, a clear IP strategy, and existing partnerships with pharma or academic institutions. The technology should be disruptive, with a clear commercial application in biotech or health tech, and the team should demonstrate the ability to execute a roadmap to clinical or market impact within 2-3 years.